Ice Cream Recall Update as FDA Issues Risk Warning
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
An Ohio creamery is recalling several of its ice cream flavors because of undeclared allergens.
Turkeyfoot Creek Creamery, based in Wauseon, issued a voluntary recall for multiple pint-size products that were distributed to six retail locations. The affected items have been pulled from store shelves.
Newsweek has contacted Turkeyfoot Creek Creamery for comment via email.
Why It Matters
According to the FDA, millions of people in the U.S. have food allergies or food sensitivities. Food sensitivities can range from mild reactions to potentially life-threatening symptoms. The agency recognizes nine major food allergens: milk, eggs, sesame, fish, tree nuts, crustacean shellfish, peanuts, wheat and soybeans.
A stock image of a spoon in vanilla ice cream.
A stock image of a spoon in vanilla ice cream.
Sven Hoppe/picture-alliance/dpa/AP
What To Know
The recall affects pints of Mocha, Cacao, Cookie Dough, Cookies and Cream, Cacao Brownie Bites, Chocolate Peanut Butter and Avalanche—all of which may contain undeclared soy and/or wheat.
The FDA has classified the recall as a Class II health risk. This classification is used when exposure to a product may cause temporary or medically reversible health consequences, or when the probability of serious adverse health effects is remote.
While no illnesses have been reported so far, the presence of undeclared allergens poses a potential risk to consumers with soy or wheat allergies.
In sensitive individuals, soy can trigger reactions ranging from mild symptoms—such as hives and stomach cramps—to severe anaphylaxis. Wheat allergies can cause similar symptoms—including respiratory issues, skin reactions and, in some cases, life-threatening allergic responses.
Because these allergens were not properly listed in the "Contains" statement on the packaging, affected consumers may unknowingly ingest ingredients that could endanger their health.
The recalled ice cream pints, all of which were individually packaged in paper cartons with paper lids, were distributed to six retailers across Indiana, Michigan and Ohio. All expiration dates are included in the recall, with markings located on the bottom of each carton.
"There have been no reports of illness involving products addressed in this recall, however, individuals exhibiting signs or symptoms of an allergic reaction after consuming Turkeyfoot Creek Creamery Ice Cream involved in this recall should contact a physician immediately," according to a news release from the Ohio Department of Agriculture.
What Happens Next
Consumers who have purchased the affected products are urged not to consume them and to return them to the place of purchase for a full refund.
Those with questions can call 419-583-7124.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Sarepta Needs to Show FDA Elevidys Won't Cause More Deaths
The Food and Drug Administration won't sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to the market until the company can persuade US regulators that it won't cause more deaths, according to an official familiar with the situation. The FDA has not seen a convincing explanation as to why Sarepta's gene therapy for Duchenne muscular dystrophy, Elevidys, was tied to two fatal cases of liver failure, the official said, and there may be no single, easily addressable problem the company can quickly fix. A third fatal case of liver failure that occurred during a trial of a separate but similar Sarepta gene therapy is unquestionably relevant information to the safety of Elevidys, said the official, who declined to be identified because the agency's deliberations are private.
Chicago Tribune
2 hours ago
- Chicago Tribune
Oak Lawn bans kratom and THC products, though won't enforce for now
Despite the Oak Lawn Village Board voting Tuesday to prohibit the sale of kratom and THC products, Mayor Terry Vorderer says the village will wait to enforce the law. The prohibition of kratom and THC products, including Delta-9, was added to the tobacco retail regulation ordinance. But Vorderer said he learned from attorneys after the vote the ordinance may need to be reworked. 'They explained that that product is not really a tobacco product,' Vorderer said Wednesday. 'Thus, I instructed our staff not to enforce the kratom part, and we'll go back and modify or look at that.' The board tabled the measure after a June 24 meeting attendee attested to the benefits of kratom, saying he would do more research on the product. Kratom is an herbal substance from Southeast Asia commonly used for pain relief, mood enhancement and withdrawal symptoms. Though it is not regulated by the United State Food and Drug Administration, the FDA estimates about 2 million Americans used kratom in 2021. The ordinance amendment passed Tuesday stated the village was experiencing 'a proliferation of retail stores selling products containing potentially intoxicating ingredients,' including kratom and THC. 'These unregulated products result in certain adverse effects, including hallucination, vomiting, tremors, anxiety, dizziness, confusion and loss of consciousness, as well as negative impacts on certain brain functions related to memory, learning, decision making and emotions,' the ordinance states. Nearby communities have similarly worked to ban the sale of kratom and other drug products. In Tinley Park, the sale, distribution and use of kratom were made illegal last year, though businesses primarily profiting from kratom sales were given a 12-month amnesty period. The Orland Park Village Board passed a similar ordinance last May, banning kratom, tianeptine, Delta-8, and other novel synthetic and psychoactive drug products. Vorderer said he has worked to regulate the sales of drug products in Oak Lawn, saying 'we don't want to be in the drug dispensing business.' He said the Village Board previously voted not to allow marijuana dispensaries and capped the number of tobacco retailers at 12. Vorderer acknowledged he still has a lot to learn about products like kratom and their purported medical benefits and continues to discuss the affects of regulation with business owners. While for now the ban will not be enforced, village staff members will advise businesses if that changes, he said.
Engadget
2 hours ago
- Engadget
FDA employees say the agency's Elsa generative AI hallucinates entire studies
Current and former members of the FDA told CNN about issues with the Elsa generative AI tool unveiled by the federal agency last month. Three employees said that in practice, Elsa has hallucinated nonexistent studies or misrepresented real research. "Anything that you don't have time to double-check is unreliable," one source told the publication. "It hallucinates confidently." Which isn't exactly ideal for a tool that's supposed to be speeding up the clinical review process and aiding with making efficient, informed decisions to benefit patients. Leadership at the FDA appeared unfazed by the potential problems posed by Elsa. "I have not heard those specific concerns," FDA Commissioner Marty Makary told CNN . He also emphasized that using Elsa and participating in the training to use it are currently voluntary at the agency. The CNN investigation highlighting these flaws with the FDA's artificial intelligence arrived on the same day as the White House introduced an " AI Action Plan ." The program presented AI development as a technological arms race that the US should win at all costs, and it laid out plans to remove "red tape and onerous regulation" in the sector. It also demanded that AI be free of "ideological bias," or in other words, only following the biases of the current administration by removing mentions of climate change, misinformation, and diversity, equity and inclusion efforts. Considering each of those three topics has a documented impact on public health, the ability of tools like Elsa to provide genuine benefits to both the FDA and to US patients looks increasingly doubtful.
